Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Biopsychosocial predictors of postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal atrophy, cognitive-emotional factors, and dyadic adjustment.

Kao A, Binik YM, Amsel R, Funaro D, Leroux N, Khalifé S.

J Sex Med. 2012 Aug;9(8):2066-76. doi: 10.1111/j.1743-6109.2012.02771.x. Epub 2012 May 23.

PMID:
22621792
2.

Acceptance of vulvovaginal pain in women with provoked vestibulodynia and their partners: associations with pain, psychological, and sexual adjustment.

Boerner KE, Rosen NO.

J Sex Med. 2015 Jun;12(6):1450-62. doi: 10.1111/jsm.12889. Epub 2015 Apr 13.

PMID:
25869256
3.

To say or not to say: Dyadic ambivalence over emotional expression and its associations with pain, sexuality, and distress in couples coping with provoked vestibulodynia.

Awada N, Bergeron S, Steben M, Hainault VA, McDuff P.

J Sex Med. 2014 May;11(5):1271-82. doi: 10.1111/jsm.12463. Epub 2014 Feb 19.

PMID:
24548305
4.

Challenging atrophied perspectives on postmenopausal dyspareunia: a systematic description and synthesis of clinical pain characteristics.

Kao A, Binik YM, Amsel R, Funaro D, Leroux N, Khalifé S.

J Sex Marital Ther. 2012;38(2):128-50. doi: 10.1080/0092623X.2011.569641.

PMID:
22390529
5.

History of sexual and physical abuse in women with dyspareunia: association with pain, psychosocial adjustment, and sexual functioning.

Leclerc B, Bergeron S, Binik YM, Khalifé S.

J Sex Med. 2010 Feb;7(2 Pt 2):971-80. doi: 10.1111/j.1743-6109.2009.01581.x. Epub 2009 Nov 13.

PMID:
19912492
6.

The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.

Cui Y, Zong H, Yan H, Li N, Zhang Y.

J Sex Med. 2014 Feb;11(2):487-97. doi: 10.1111/jsm.12377. Epub 2013 Nov 20. Review.

PMID:
24251418
7.

Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.

McLendon AN, Clinard VB, Woodis CB.

Pharmacotherapy. 2014 Oct;34(10):1050-60. doi: 10.1002/phar.1465. Epub 2014 Jul 23. Review.

PMID:
25052122
8.

Dyspareunia in postmenopausal women: a critical review.

Kao A, Binik YM, Kapuscinski A, Khalife S.

Pain Res Manag. 2008 May-Jun;13(3):243-54. Review.

9.

Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.

Kingsberg SA, Wysocki S, Magnus L, Krychman ML.

J Sex Med. 2013 Jul;10(7):1790-9. doi: 10.1111/jsm.12190. Epub 2013 May 16.

PMID:
23679050
10.

Affect and marital adjustment in women's rating of dyspareunic pain.

Meana M, Binik I, Khalife S, Cohen D.

Can J Psychiatry. 1998 May;43(4):381-5.

PMID:
9598275
11.

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.

Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É; VVA Prasterone Research Group.

Menopause. 2016 Mar;23(3):243-56. doi: 10.1097/GME.0000000000000571.

PMID:
26731686
12.

Dyadic sexual communication in pre-menopausal women with self-reported dyspareunia and their partners: associations with sexual function, sexual distress and dyadic adjustment.

Pazmany E, Bergeron S, Verhaeghe J, Van Oudenhove L, Enzlin P.

J Sex Med. 2015 Feb;12(2):516-28. doi: 10.1111/jsm.12787. Epub 2014 Dec 5.

PMID:
25475508
13.

Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.

Bachmann GA, Komi JO; Ospemifene Study Group.

Menopause. 2010 May-Jun;17(3):480-6. doi: 10.1097/gme.0b013e3181c1ac01.

PMID:
20032798
14.

Aspects of sexual self-schema in premenopausal women with dyspareunia: associations with pain, sexual function, and sexual distress.

Pazmany E, Bergeron S, Van Oudenhove L, Verhaeghe J, Enzlin P.

J Sex Med. 2013 Sep;10(9):2255-64. doi: 10.1111/jsm.12237. Epub 2013 Jul 11.

PMID:
23845053
15.

Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions.

Palacios S, Cancelo MJ, Castelo Branco C, Llaneza P, Molero F, Borrego RS.

Climacteric. 2017 Feb;20(1):55-61. doi: 10.1080/13697137.2016.1262840. Epub 2017 Jan 2.

PMID:
28042734
16.

Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.

Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É; Members of the VVA Prasterone Research Group.

J Sex Med. 2015 Dec;12(12):2401-12. doi: 10.1111/jsm.13045. Epub 2015 Nov 23.

PMID:
26597311
17.

Provoked Vestibulodynia: Does Pain Intensity Correlate With Sexual Dysfunction and Dissatisfaction?

Aerts L, Bergeron S, Pukall CF, Khalifé S.

J Sex Med. 2016 Jun;13(6):955-62. doi: 10.1016/j.jsxm.2016.03.368. Epub 2016 Apr 12.

PMID:
27080365
18.

Do romantic partners' responses to entry dyspareunia affect women's experience of pain? The roles of catastrophizing and self-efficacy.

Lemieux AJ, Bergeron S, Steben M, Lambert B.

J Sex Med. 2013 Sep;10(9):2274-84. doi: 10.1111/jsm.12252. Epub 2013 Jun 27.

PMID:
23809759
19.

Attributions about pain as predictors of psychological symptomatology, sexual function, and dyadic adjustment in women with vestibulodynia.

Jodoin M, Bergeron S, Khalifé S, Dupuis MJ, Desrochers G, Leclerc B.

Arch Sex Behav. 2011 Feb;40(1):87-97. doi: 10.1007/s10508-010-9647-7. Epub 2010 Jul 23.

PMID:
20652736
20.

A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study.

Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, Candiani M, Leone Roberti Maggiore U.

Climacteric. 2014 Aug;17(4):363-9. doi: 10.3109/13697137.2014.899347. Epub 2014 Jun 5.

PMID:
24605832

Supplemental Content

Support Center